Trametinib: This is a medication taken by mouth daily. It is a type of drug known as a MEK inhibitor. In this trial, it is being tested to see if it can improve treatment outcomes for patients with a specific type of brain tumor called low-grade glioma, which has a normal BRAF gene. The goal is to see if Trametinib can be more effective than the current standard treatment.

Vinblastine: This is a medication given through an intravenous (IV) injection once a week. It is a type of chemotherapy used as a standard treatment for certain types of cancer, including low-grade glioma. In this trial, Vinblastine is being used as a comparison to see if the new treatment with Trametinib offers better results for patients.

Grade 1 Glioma – This is a type of brain tumor that originates from glial cells, which are supportive cells in the brain. It is considered a low-grade tumor, meaning it grows slowly and is less aggressive compared to higher-grade gliomas. These tumors can cause symptoms depending on their location in the brain, such as headaches, seizures, or neurological deficits. Over time, they may increase in size, potentially leading to more pronounced symptoms. Despite their slow growth, they can still impact brain function and require monitoring.

Mixed Glio-Neuronal Tumors – These are rare brain tumors that contain both glial and neuronal cell components. They typically occur in children and young adults and are generally considered low-grade, meaning they grow slowly. Symptoms can vary widely depending on the tumor’s location but may include seizures, headaches, or other neurological issues. The progression of these tumors is usually slow, but they can still cause significant symptoms over time. Regular monitoring is often necessary to assess any changes in the tumor’s behavior.

Pleomorphic Xanthoastrocytoma (PXA) – This is a rare type of brain tumor that usually affects children and young adults. It is typically a low-grade tumor, meaning it grows slowly and is less likely to spread. PXAs often occur in the cerebral hemispheres and can cause symptoms such as seizures or headaches. Despite their generally slow growth, they can sometimes become more aggressive. Monitoring and follow-up are important to manage any changes in the tumor’s characteristics.